Network meta-analysis and cost-effectiveness analysis comparing Cetuximab-β and Cetuximab for Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer.

ABSTRACT:

Background

The escalating economic burden of metastatic colorectal cancer (mCRC) in China necessitates cost-effective first-line treatments. Cetuximab-β, a newer version of Cetuximab, is approved for first-line RAS/BRAF wild-type mCRC. This study evaluates the cost-effectiveness of Cetuximab-β with FOLFIRI for mCRC patients, comparing it to Cetuximab plus chemotherapy to guide clinical decision-making and policy development.

Methods

We conducted a network meta-analysis (NMA) of six randomized controlled trials to compare overall survival (OS), progression-free survival (PFS), and adverse events (AEs). Subsequently, a cost-effectiveness analysis (CEA) was performed using a 10-year partitioned survival model from the Chinese healthcare payer perspective. Costs were standardize

SUBMITTER: Tong R 

PROVIDER: S-EPMC12477409 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature